Halixol syrup 3mg/ml 100ml №1

Name:
Halixol syrup 3mg/ml in vial 100ml in pack. No. 1
Description:
The syrup is colorless or pale yellow, transparent, without sediment, with a characteristic odor. The main active ingredient Ambroxol Release form Colorless or pale yellow syrup, transparent, without sediment, with a characteristic odor. 10 ml Active substance: ambroxol hydrochloride 30 mg; Excipients: sorbitol, povidone K90, citric acid monohydrate, sodium cyclamate, strawberry flavor 22754, banana flavor 270650, sodium benzoate, sodium citrate, purified water. 100 ml – brown glass bottles with a white aluminum cap with first opening control (1) complete with a measuring cup – packs of cardboard. Dosage 3mg/ml in vial 100ml in pack. No. 1 Special instructions Should not be administered simultaneously with antitussive drugs due to difficulty in sputum production. The use of the drug in patients with impaired motor function of the bronchi or profuse sputum with low viscosity requires caution because of the risk of stagnation of bronchial secretions. The syrup contains non-specific sweeteners, sorbitol, sodium cyclamate, so patients with diabetes can use this drug, but the content of sorbitol (1.2 g per 5 ml) should be taken into account by patients with diabetes. The drug does not contain alcohol. Pharmacological action Expectorant (mucolytic) drug. Ambroxol is an active metabolite of bromhexine, belongs to the benzylamine group of mucolytic substances. Liquefies sputum by increasing the production and activity of hydrolytic enzymes that break down bonds between sputum mucopolysaccharides. Improves the rheological properties of sputum, reducing its viscosity and adhesive properties, by stimulating the serous cells of the glands of the bronchial mucosa and normalizing the ratio of the mucous and serous components of sputum. Increases mucociliary transport, increasing the motor activity of the ciliated epithelium. Does not cause excessive secretion, reduces spastic bronchial hyperreactivity. Promotes the production of surfactant. The effect develops 30 minutes after taking the drug. Pharmacokinetics Absorption After oral administration, it is almost completely absorbed from the gastrointestinal tract. Bioavailability after oral administration is approximately 60%. The time to reach Cmax in plasma is 2 hours. Distribution Plasma protein binding is about 80%. Penetrates through the placental barrier. Its concentration in the body of the fetus is 2-4 times higher than that of the mother. Found in breast milk and cerebrospinal fluid. Metabolism Exposed to active metabolism during the “first pass” through the liver. Excretion T1 / 2 is about 7 hours. About 90% of the dose taken is excreted in the urine in the form of a glucuronide conjugate of ambroxol or oxidized products of its metabolism. Pharmacokinetics in special clinical cases T1 / 2 increases with severe renal failure, does not change with impaired liver function. Indications for use Acute and chronic diseases of the respiratory system, accompanied by the formation of viscous sputum: bronchitis, bronchial asthma, chronic obstructive pulmonary disease, pneumonia, bronchiectasis; inflammatory diseases of the ENT organs (sinusitis, otitis media), in which mucus thinning is necessary. Dosage and administrationtext Use during pregnancy and lactation The drug is contraindicated for use in the first trimester of pregnancy. Ambroxol is excreted in breast milk, therefore, if it is necessary to use the drug during lactation, the issue of stopping breastfeeding should be resolved. Precautions Do not administer simultaneously with antitussive drugs due to difficulty in sputum production. The use of the drug in patients with impaired motor function of the bronchi or profuse sputum with low viscosity requires caution because of the risk of stagnation of bronchial secretions. The syrup contains non-specific sweeteners, sorbitol, sodium cyclamate, so patients with diabetes can use this drug, but the content of sorbitol (1.2 g per 5 ml) should be taken into account by patients with diabetes. The drug does not contain alcohol. Interaction with other drugs Antitussive drugs (including codeine) can make it difficult to excrete sputum diluted with ambroxol. Halixol® promotes the penetration of certain antibiotics into the bronchial secret (including amoxicillin, cefuroxime, erythromycin, doxycycline). Contraindications Ulcerative lesion of the gastrointestinal tract; I trimester of pregnancy; lactation period (breastfeeding); hypersensitivity to ambroxol or bromhexine; The drug should be used with caution in severe renal failure. Composition Active substance: ambroxol hydrochloride 30 mg; Excipients: sorbitol, povidone K90, citric acid monohydrate, sodium cyclamate, strawberry flavor 22754, banana flavor 270650, sodium benzoate, sodium citrate, purified water. Overdose Symptoms: nausea, vomiting, diarrhea, dyspepsia. Treatment: induce vomiting, then prescribe a drink (milk or tea), intake of fat-containing foods. Gastric lavage is recommended within 1-2 hours after taking the drug. The function of the cardiovascular system should be constantly monitored. Side effect From the side of the central nervous system: rarely – weakness, headache. From the digestive system: rarely – diarrhea, constipation, dry mouth, gastralgia, nausea, vomiting. From the respiratory system: rarely – dryness of the respiratory tract, rhinorrhea. Allergic reactions: rarely – exanthema, urticaria; extremely rarely – acute anaphylactic reactions, the causal relationship of which with the use of ambroxol has not been established. Other: dysuria. Halixol is generally well tolerated. Storage conditions The drug should be stored at a temperature of 15 ° to 25 ° C, out of the reach of children. Buy Halixol syrup 3mg/ml 100ml №1